Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline ALK inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides a detailed information about discontinued and dormant drugs.View report: https://www.arizton.com/reports/pharma-pipeline-analysis/anaplastic-lymphoma-kinase-alk-inhibitors-pipeline-insights
The report profiles key players in developing potential ALK drug candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.
Scope
Provides in-depth insights about active Anaplastic Lymphoma Kinase (ALK) inhibitors pipeline drug candidates
Offers an extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery
Provides pipeline assessment by monotherapy, combination therapy products, and route of administration
Provides comparative analysis of key marketed and pipeline Anaplastic Lymphoma Kinase (ALK) inhibitors
Includes coverage of detailed pipeline drug profiles, which include product description, chemical information, MOA, licensors and collaborators, development partner
Analyzes key players involved in clinical research and development of the ALK inhibitors
Provides the coverage of key news related to ALK inhibitors, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) belonging to the insulin receptor (IR) superfamily. ALK also known CD246 is encoded by the ALK gene in humans. Immunohistochemical analysis of adult human tissues reveals that ALK expression is sparsely scattered in neural cells, endothelial cells and pericytes in the brain. ALK mRNA is also expressed in the small intestine, testis, prostate, and colon. ALK was initially identified as the product of a gene rearrangement in anaplastic large cell lymphoma (ALCL). ALK was subsequently found to be rearranged, mutated, or amplified in a series of tumors including lymphoma, neuroblastoma, and non-small cell lung cancer (NSCLC). There is strong clinical evidence that ALK is one a key driving factor of oncogenesis, thus making it a key drug target.
Currently marketed ALK inhibitors include Zykadia (ceritinib) and Alecensa (alectinib). These drugs are indicated for the treatment of gastrointestinal cancer and non small cell lung cancer. The ALK inhibitors pipeline has more than 15 molecules and is expected to achieve regulatory approval in foreseeable future, few of which are ensartinib (X-396), X-376, X-390, CEP-28122, EBI-215, EBI-600215, and ASP3026. In pipeline analysis, these are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and pre-clinical stage. Few key companies which are involved in the development of ALK inhibitors include AstraZeneca, Teva, Delenex Therapeutics, Astellas, Amgen and Tesaro.
Reasons to Buy
To gain erudite insights about the ALK inhibitor pipeline landscape
To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
To identify competitors and design strategic initiatives for drug development activities
To understand the market and choose right partners for strategic collaborations
To obtain informed updates on drug termination/drug discontinuation
View report: https://www.arizton.com/reports/pharma-pipeline-analysis/anaplastic-lymphoma-kinase-alk-inhibitors-pipeline-insights
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging
Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017 here
News-ID: 790490 • Views: …
More Releases from Arizton Advisory & Intelligence
The US Glamping Market Forecasted to Reach New Heights, More than $1.3 Billion R …
According to Arizton's latest research report, the US glamping market is growing at a CAGR of 15.14% during 2023-2029.
To Know More, Click: https://www.arizton.com/market-reports/united-states-glamping-market
Growth in Luxury Travel Activities Gaining Traction in the US Glamping Market
Glamping is a niche within the travel industry that appeals to luxury travelers with discerning tastes. Unlike those who prefer business class flights or opulent hotel rooms, glampers seek more than just lavish accommodations; they crave meaningful…
The U.S. Water Heater Market to Reach USD 5.08 billion by 2029, Growing at a CAG …
According to Arizton's latest research report, the US water heater market is growing at a CAGR of 6.67% from 2023 to 2029.
To Know More, Click: https://www.arizton.com/market-reports/us-water-heater-market
Browse in-depth TOC on the U.S. Water Heater Market
201 - Pages
92 - Tables
62- Figures
Integrating smart home technologies allows controlling and monitoring water heaters remotely using mobile apps. Smart features, including energy usage tracking and remote…
The Global Home Energy Management System Market to Reach $9.41 Billion by 2029, …
According to Arizton's latest research report, the global home energy management system market is growing at a CAGR of 15.23% during the forecast period.
To Know More, Download the Free Sample Report: https://www.arizton.com/market-reports/home-energy-management-system-market
Increasing Investment in Residential Construction Projects Boosts Home Energy Management System Market
The demand for smart home technologies will grow rapidly over the next few years. A significant share of expenditure on smart homes comprises IoT and networked appliances in…
The Global Roofing Market to Reach $277.66 Billion by 2028, Growing at a CAGR of …
According to Arizton's latest research report, the global roofing market is growing at a CAGR of 5.10% 2024-2029.
To Know More, Download the Free Sample Report: https://www.arizton.com/market-reports/roofing-market
The new construction application segment held the most significant share of the global roofing market in 2022 and is expected to continue the trend during the forecast period. One key factor supporting the segmental growth is the overall growth of new construction projects, driven…
More Releases for ALK
Epinephrine Market 2017 - Pfizer, Mylan, Sanofi, ALK Abello, Hospira
Apex Market Reports, recently published a detailed market research study focused on the "Epinephrine Market" across the global, regional and country level. The report provides 360° analysis of "Epinephrine Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Epinephrine industry, and estimates the future trend of Epinephrine market on the basis of…
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…
GLOBAL EPINEPHRINE AUTOINJECTOR MARKET- MYLAN, SANOFI, ALK, ABELLO, IMPAX
Global Industry Study Evaluate on Epinephrine Autoinjector Market by Type, Manufacturers, Regions, and Application, Forecast up to 2022
The scope of the Epinephrine Autoinjector Report:
This report primarily focuses on Epinephrine Autoinjector in the global market. This report generally covers Epinephrine Autoinjector market in North America, Epinephrine Autoinjector market in Asia-Pacific, Epinephrine Autoinjector market in Europe, Epinephrine Autoinjector market in Latin America, Middle as well as Africa. This report partitions the Epinephrine…
Global Epinephrine Autoinjector Market 2017 - Mylan, Impax, Sanofi, ALK Abello
An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in the 1980s.
Major players in the global Epinephrine Autoinjector market :-
1 Mylan (USA)
2 Impax (USA)
3 Sanofi (France)
4 ALK Abello (Denmark)
Request for sample @ https://goo.gl/inqVd7
This report provides detailed analysis of…